Beclovent
(Beclomethasone Dipropionate 640)PreclinicalSmall molecule
Beclovent is one of 40 small molecule programs targeting Allergic Rhinitis. It is currently in Preclinical.
1
Indications
6
Total Trials
0
Active Trials
39
Competitors
11
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Singulair
OOrganon and Co
Approved
Flovent
PParatek Pharmaceuticals Inc
Approved
Xyzal
CChattem
Approved
Alvesco
AAzurity Pharmaceuticals
Approved
Claritin
PPerrigo Company
Approved
Clarinex
OOrganon and Co
Approved
Zyrtec
KKenvue Brands
Approved
Pulmicort
SSalix
Approved
Qvar
SSchering-Plough
Approved
Allegra
CChattem
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Asthma3 trials
Allergic Rhinitis1 trial
Efficacy and Safety1 trial
Adult1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
BECONASE
NDA NDA018584
Jan 1, 1982
VANCERIL
NDA NDA017573
Jan 1, 1982
BECLOVENT
NDA NDA018153
Jan 1, 1982
VANCENASE
NDA NDA018521
Jul 27, 1987
BECONASE AQ
NDA NDA019389
Dec 23, 1987
VANCENASE AQ
NDA NDA019589
Jun 26, 1996
VANCENASE AQ
NDA NDA020469
Dec 24, 1996
VANCERIL DOUBLE STRENGTH
NDA NDA020486
Sep 15, 2000
QVAR 40
NDA NDA020911
Dec 17, 2014
QNASL
NDA NDA202813
Aug 3, 2017
QVAR REDIHALER
NDA NDA207921
Sources
References
- [1]
- [2]
- [3]
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSchering-Plough